抗耳念珠菌药物的研究进展  

Research progress of antifungal agents against Candida auris

作　　者：林敬生 涂杰 盛春泉 LIN Jingsheng;TU Jie;SHENG Chunquan(School of Pharmaceutial Engineerring,Shenyang Pharmaceutical University,Benxi 117004,China;School of Pharmacy,Second Military Medical University(Navy Medical University),Shanghai 200433,China)

机构地区：[1]沈阳药科大学制药工程学院,辽宁本溪117004 [2]中国人民解放军海军军医大学药学院,上海200433

出　　处：《沈阳药科大学学报》2023年第12期1645-1655,共11页Journal of Shenyang Pharmaceutical University

基　　金：国家自然科学基金重点项目(82330109);上海市教委科研创新计划重大项(2019-01-07-00-07-E00073)。

摘　　要：耳念珠菌于2009年首次分离得到,具有严重的多药耐药性和极强的皮肤定植、环境污染能力,在全球范围内迅速传播,被称为“超级真菌”。目前临床上传统的抗真菌药物对耳念珠菌感染的治疗效果相当有限。本文基于羊毛甾醇14α-去甲基化酶、β-1,3-D-葡聚糖合成酶、糖基磷脂酰肌醇锚定蛋白、线粒体、细胞核酸和几丁质等抗真菌靶点,重点介绍近年来用于抗耳念珠菌感染的上市药物和临床候选药物。本文综述了耳念珠菌的耐药现状和耐药机制,并详细阐述了新型上市和临床候选药物的化学结构和抗真菌药效,为进一步指导抗耳念珠菌药物的研发提供有价值的参考。Candida auris was first isolated in 2009,which exhibits a high level of multidrug resistance and ability of skin colonization and environmental contamination, and has spread rapidly around the world since then, and was called “super fungus”.Currently, the treatment effect of traditional antifungal agents on Candida auris infection is rather limited.Based on the antifungal targets of lanosterol 14α-demethylase, β-1,3-D-glucan synthetase, glycosylphosphatidylinositol anchor protein, mitochondria, cell nucleic acid and chitin, this paper focuses on the marketed drugs and clinical candidate drugs against Candida auris infection in recent years.In this review, we describe the current resistance status and mechanisms of Candida auris,and elaborate detailly the chemical structure and antifungal efficacy of new marketed drugs and clinical candidates in order to provide valuable references for guiding the further drug research and development of drugs against Candida auris.

关 键 词：耳念珠菌 抗真菌药物 耐药真菌 药物研发 抗真菌靶点 

分 类 号：R978[医药卫生—药品]